MétaCan
Menu
Back to cohort
Record W2735011415 · doi:10.18632/oncotarget.19204

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy

2017· article· en· W2735011415 on OpenAlexafffundabout
Brent A. Williams, Arjun Law, Bertrand Routy, Neal denHollander, Vikas Gupta, Xinghua Wang, A. Chaboureau, Sowmya Viswanathan, Armand Keating

Bibliographic record

VenueOncotarget · 2017
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmune Cell Function and Interaction
Canadian institutionsUniversity Health NetworkPrincess Margaret Cancer Centre
FundersUniversity of TorontoOntario Institute for Cancer ResearchPrincess Margaret Hospital Foundation
KeywordsMedicineChillsInternal medicineRefractory (planetary science)TransplantationLymphomaMultiple myelomaHematopoietic stem cell transplantationClinical trialOncologyGastroenterologyImmunologyBiology

Abstract

fetched live from OpenAlex

// Brent A. Williams 1 , Arjun Datt Law 1 , Bertrand Routy 1 , Neal denHollander 2 , Vikas Gupta 1 , Xing-Hua Wang 1 , Amélie Chaboureau 1 , Sowmya Viswanathan 1 and Armand Keating 1 1 Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada 2 Department of Laboratory Medicine, University Health Network, Toronto, ON, Canada Correspondence to: Armand Keating, email: armand.keating@uhn.ca Keywords: NK cell, NK-92, clinical trial, lymphoma, multiple myeloma Received: May 31, 2017      Accepted: June 28, 2017      Published: July 12, 2017 ABSTRACT Background: Autologous NK cell therapy can treat a variety of malignancies, but is limited by patient-specific variations in potency and cell number expansion. In contrast, allogeneic NK cell lines can overcome many of these limitations. Cells from the permanent NK-92 line are constitutively activated, lack inhibitory receptors and appear to be safe based on two prior phase I trials. Materials and Methods: We conducted a single-center, non-randomized, non-blinded, open-label, Phase I dose-escalation trial of irradiated NK-92 cells in adults with refractory hematological malignancies who relapsed after autologous hematopoietic cell transplantation (AHCT). The objectives were to determine safety, feasibility and evidence of activity. Patients were treated at one of three dose levels (1 × 10 9 cells/m 2 , 3 × 10 9 cells/m 2 and 5 × 10 9 cells/m 2 ), given on day 1, 3 and 5 for a planned total of six monthly cycles. Results: Twelve patients with lymphoma or multiple myeloma who relapsed after AHCT for relapsed/refractory disease were enrolled in this trial. The treatment was well tolerated, with minor toxicities restricted to acute infusional events, including fever, chills, nausea and fatigue. Two patients achieved a complete response (Hodgkin lymphoma and multiple myeloma), two patients had minor responses and one had clinical improvement on the trial. Conclusions: Irradiated NK-92 cells can be administered at very high doses with minimal toxicity in patients with refractory blood cancers, who had relapsed after AHCT. We conclude that high dose NK-92 therapy is safe, shows some evidence of efficacy in patients with refractory blood cancers and warrants further clinical investigation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0010.002
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.297
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations187
Published2017
Admission routes3
Has abstractyes

Explore more

Same venueOncotargetSame topicImmune Cell Function and InteractionFrench-language works237,207